Similar articles for PMID: 23097455

Year	Number of Results
1996	1
1998	1
1999	1
2000	1
2001	1
2002	2
2004	1
2005	1
2006	1
2007	4
2008	4
2009	4
2010	6
2011	12
2012	11
2013	10
2014	5
2015	7
2016	7
2017	8
2018	6
2019	10
2020	3
2021	1
2022	2
2023	2
2024	0

1

Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, Xia J, Patel AH, Bukh J, Foung SK. Keck Z, et al. J Virol. 2013 Jan;87(1):37-51. doi: 10.1128/JVI.01941-12. Epub 2012 Oct 24. J Virol. 2013. PMID: 23097455 Free PMC article.

2

Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.

Keck ZY, Girard-Blanc C, Wang W, Lau P, Zuiani A, Rey FA, Krey T, Diamond MS, Foung SK. Keck ZY, et al. J Virol. 2016 Jan 6;90(6):3112-22. doi: 10.1128/JVI.02458-15. J Virol. 2016. PMID: 26739044 Free PMC article.

3

Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423.

Keck ZY, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, Patel AH, Foung SK. Keck ZY, et al. PLoS Pathog. 2014 Aug 14;10(8):e1004297. doi: 10.1371/journal.ppat.1004297. eCollection 2014 Aug. PLoS Pathog. 2014. PMID: 25122476 Free PMC article.

4

Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK. Keck ZY, et al. PLoS Pathog. 2012;8(4):e1002653. doi: 10.1371/journal.ppat.1002653. Epub 2012 Apr 12. PLoS Pathog. 2012. PMID: 22511875 Free PMC article. Clinical Trial.

5

Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.

Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang ST, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S. Costin JM, et al. J Virol. 2013 Jan;87(1):52-66. doi: 10.1128/JVI.02273-12. Epub 2012 Oct 17. J Virol. 2013. PMID: 23077306 Free PMC article.

6

Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.

Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH. Keck ZY, et al. PLoS Pathog. 2019 May 17;15(5):e1007772. doi: 10.1371/journal.ppat.1007772. eCollection 2019 May. PLoS Pathog. 2019. PMID: 31100098 Free PMC article.

7

Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2.

Keck ZY, Li TK, Xia J, Bartosch B, Cosset FL, Dubuisson J, Foung SK. Keck ZY, et al. J Virol. 2005 Nov;79(21):13199-208. doi: 10.1128/JVI.79.21.13199-13208.2005. J Virol. 2005. PMID: 16227243 Free PMC article.

8

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM, Foung SK. Keck ZY, et al. J Virol. 2009 Jun;83(12):6149-60. doi: 10.1128/JVI.00248-09. Epub 2009 Mar 25. J Virol. 2009. PMID: 19321602 Free PMC article.

9

Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.

Pierce BG, Keck ZY, Wang R, Lau P, Garagusi K, Elkholy K, Toth EA, Urbanowicz RA, Guest JD, Agnihotri P, Kerzic MC, Marin A, Andrianov AK, Ball JK, Mariuzza RA, Fuerst TR, Foung SKH. Pierce BG, et al. J Virol. 2020 Oct 27;94(22):e00704-20. doi: 10.1128/JVI.00704-20. Print 2020 Oct 27. J Virol. 2020. PMID: 32878891 Free PMC article.

10

Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK. Keck ZY, et al. J Virol. 2011 Oct;85(20):10451-63. doi: 10.1128/JVI.05259-11. Epub 2011 Aug 3. J Virol. 2011. PMID: 21813602 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

97 results

Results by year